2024
Intravascular Imaging–Guided Versus Angiography‐Guided Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis of Randomized Trials
Sreenivasan J, Reddy R, Jamil Y, Malik A, Chamie D, Howard J, Nanna M, Mintz G, Maehara A, Ali Z, Moses J, Chen S, Chieffo A, Colombo A, Leon M, Lansky A, Ahmad Y. Intravascular Imaging–Guided Versus Angiography‐Guided Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis of Randomized Trials. Journal Of The American Heart Association 2024, 13: e031111. PMID: 38214263, PMCID: PMC10926835, DOI: 10.1161/jaha.123.031111.Peer-Reviewed Original ResearchConceptsAdverse cardiac eventsPercutaneous coronary interventionAngiography-guided percutaneous coronary interventionTarget vessel revascularizationTarget-lesion revascularizationCardiac eventsCardiac deathImaging-guided percutaneous coronary interventionWeighted mean follow-up durationMeta-analysisPrimary outcomeMean follow-up durationStent thrombosisMeta-analysis of randomized trialsStudy-level meta-analysisComplex lesion subsetsIntravascular imagingAll-cause deathRandom-effects meta-analysisStandard of careIntention-to-treat principleUpdates of clinical guidelinesMixed-effects meta-regressionComplex percutaneous coronary interventionIntravascular imaging-guided percutaneous coronary intervention
2023
Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes
Frampton J, Kearney K, Abbott J, Kereiakes D, Di Mario C, Saito S, Cristea E, Riley R, Fajadet J, Shlofmitz R, Ali Z, Klein A, Price M, Hill J, Stone G, Lansky A. Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101069. PMID: 39129889, PMCID: PMC11307843, DOI: 10.1016/j.jscai.2023.101069.Peer-Reviewed Original ResearchIntravascular lithotripsyLesion failureIschemia-driven target lesion revascularizationMajor adverse cardiac event ratesAdverse cardiac event ratesDrug-eluting stent placementMajor adverse cardiac eventsSmaller reference vessel diameterTarget vessel myocardial infarctionCoronary intravascular lithotripsyAdverse cardiac eventsCardiac event ratePrimary end pointTarget lesion failureTarget lesion revascularizationVessel myocardial infarctionReference vessel diameterAdverse clinical eventsHigh procedural successSex-based outcomesSex-specific outcomesLesion revascularizationAngiographic outcomesCardiac eventsCardiac death
2022
Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III
Garot P, Leon M, Saito S, Baumbach A, Kereiakes D, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Diaz V, McLaurin B, Cequier A, Hofma S, Dib N, Namiki A, Takahashi A, Kakuta T, Hirohata A, Lansky A. Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 2: 100515. PMID: 39132534, PMCID: PMC11308104, DOI: 10.1016/j.jscai.2022.100515.Peer-Reviewed Original ResearchDrug-eluting stentsDurable polymer everolimus-eluting stentsEverolimus-eluting stentsIII trialsLesion failureClinical outcomesMyocardial infarctionMajor adverse cardiac eventsVessel-related myocardial infarctionBiodegradable polymer drug-eluting stentsAdverse cardiac eventsOutcomes of patientsTarget lesion failureTarget lesion revascularizationLesion revascularizationCardiac eventsPatient characteristicsCardiac deathDES groupProcedural successStent thrombosisSubgroup analysisPatient outcomesNonsignificant trendEnrollment locationPercutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting for Treating In-Stent Restenosis in Unprotected-Left Main: LM-DRAGON-Registry
Wańha W, Bil J, Kołodziejczak M, Kowalówka A, Kowalewski M, Hudziak D, Gocoł R, Januszek R, Figatowski T, Milewski M, Tomasiewicz B, Kübler P, Hrymniak B, Desperak P, Kuźma Ł, Milewski K, Góra B, Łoś A, Kulczycki J, Włodarczak A, Skorupski W, Grygier M, Lesiak M, D'Ascenzo F, Andres M, Kleczynski P, Litwinowicz R, Borin A, Smolka G, Reczuch K, Gruchała M, Gil RJ, Jaguszewski M, Bartuś K, Suwalski P, Dobrzycki S, Dudek D, Bartuś S, Ga̧sior M, Ochała A, Lansky AJ, Deja M, Legutko J, Kedhi E, Wojakowski W. Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting for Treating In-Stent Restenosis in Unprotected-Left Main: LM-DRAGON-Registry. Frontiers In Cardiovascular Medicine 2022, 9: 849971. PMID: 35615559, PMCID: PMC9125786, DOI: 10.3389/fcvm.2022.849971.Peer-Reviewed Original ResearchPercutaneous coronary interventionTarget vessel revascularizationCoronary artery bypassCardiac deathMyocardial infarctionPCI groupArtery bypassCoronary interventionStent restenosisUnprotected left main coronary arteryLeft main coronary arteryMain coronary arteryManagement of patientsAnalysis of patientsCerebrovascular eventsPrimary endpointVessel revascularizationConsecutive patientsCoronary arteryCABGLower incidenceLower riskPatientsDeathMACCESafety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus
Thomas A, Kereiakes D, Baumbach A, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Díaz V, McLaurin B, Cequier Á, Takahashi A, Cannon L, Amoroso G, Kakuta T, Saito S, Leon M, Lansky A. Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100033. PMID: 39132558, PMCID: PMC11307809, DOI: 10.1016/j.jscai.2022.100033.Peer-Reviewed Original ResearchTarget vessel myocardial infarctionVessel myocardial infarctionDiabetes mellitusDP-EESLesion failureIII trialsCardiac deathMyocardial infarctionBiodegradable Polymer Sirolimus-Eluting StentBiodegradable polymer sirolimus-eluting stentsTarget lesion failureTarget lesion revascularizationPercutaneous coronary interventionSirolimus-Eluting StentsLong-term inflammatory responseDiabetic subgroupsLesion revascularizationNondiabetic patientsSecondary endpointsBackground PatientsCoronary interventionPrespecified analysisComposite endpointPrimary safetyWorse outcomes
2021
Long term outcomes of ultrathin versus standard thickness second‐generation drug eluting stents: Meta‐analysis of randomized trials
Hussain Y, Gaston S, Kluger J, Shah T, Yang Y, Tirziu D, Lansky A. Long term outcomes of ultrathin versus standard thickness second‐generation drug eluting stents: Meta‐analysis of randomized trials. Catheterization And Cardiovascular Interventions 2021, 99: 563-574. PMID: 34236755, DOI: 10.1002/ccd.29866.Peer-Reviewed Original ResearchConceptsSecond generation drug eluting stentsTarget lesion failureDrug eluting stentsLong-term outcomesEluting stentsTerm outcomesRisk ratioIschemia-driven target vessel revascularizationTarget vessel myocardial infarctionLong-term clinical outcomesProbable stent thrombosisTarget vessel revascularizationTerm clinical outcomesVessel myocardial infarctionPercutaneous coronary interventionCoronary artery diseaseConfidence intervalsFirst generation drug eluting stentsRandom-effects modelLesion failureVessel revascularizationCoronary interventionSecondary outcomesArtery diseaseCardiac deathCardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis
Navarese EP, Lansky AJ, Kereiakes DJ, Kubica J, Gurbel PA, Gorog DA, Valgimigli M, Curzen N, Kandzari DE, Bonaca MP, Brouwer M, Umińska J, Jaguszewski MJ, Raggi P, Waksman R, Leon MB, Wijns W, Andreotti F. Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. European Heart Journal 2021, 42: 4638-4651. PMID: 34002203, PMCID: PMC8669551, DOI: 10.1093/eurheartj/ehab246.Peer-Reviewed Original ResearchConceptsSpontaneous myocardial infarctionStable coronary artery disease patientsCoronary artery disease patientsElective coronary revascularisationMedical therapyCardiac mortalityMyocardial infarctionCoronary revascularisationCause mortalityDisease patientsPre-specified primary endpointCoronary artery diseaseRate ratioDeath risk reductionRandom-effects modelMultivessel diseaseMortality findingsPrimary endpointSecondary endpointsStable patientsStroke riskSurvival benefitArtery diseaseCardiac deathRevascularisationWall shear stress estimated by 3D-QCA can predict cardiovascular events in lesions with borderline negative fractional flow reserve
Tufaro V, Safi H, Torii R, Koo BK, Kitslaar P, Ramasamy A, Mathur A, Jones DA, Bajaj R, Erdoğan E, Lansky A, Zhang J, Konstantinou K, Little CD, Rakhit R, Karamasis GV, Baumbach A, Bourantas CV. Wall shear stress estimated by 3D-QCA can predict cardiovascular events in lesions with borderline negative fractional flow reserve. Atherosclerosis 2021, 322: 24-30. PMID: 33706080, DOI: 10.1016/j.atherosclerosis.2021.02.018.Peer-Reviewed Original ResearchConceptsNegative fractional flow reserveCardiovascular eventsFractional flow reservePrimary endpointFlow reserveSmaller minimum lumen areaAdverse cardiovascular eventsRetrospective cohort studyTarget lesion revascularizationOnly independent predictorMinimum lumen areaQCA variablesAngiographic characteristicsLesion revascularizationCulprit lesionHighest maximum wall shear stressCohort studyCardiac deathIndependent predictorsComplete followMultivariable analysisMyocardial infarctionTarget lesionsArea stenosisNegative FFR
2019
2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent
Xu B, Saito Y, Baumbach A, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Lansky A, Wijns W, Investigators T. 2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. JACC Cardiovascular Interventions 2019, 12: 1679-1687. PMID: 31129092, DOI: 10.1016/j.jcin.2019.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedCardiovascular AgentsCoronary Artery DiseaseCoronary ThrombosisDrug-Eluting StentsDual Anti-Platelet TherapyEuropeEverolimusFemaleHumansMaleMiddle AgedPercutaneous Coronary InterventionPolymersProspective StudiesProsthesis DesignRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsTarget lesion failureXIENCE stentXience groupLesion failurePrimary endpointClinical outcomesIschemia-driven target lesion revascularizationTarget vessel myocardial infarctionProbable stent thrombosisTarget lesion revascularizationVessel myocardial infarctionLong-term outcomesDurable polymer everolimusBiodegradable Polymer SirolimusAbluminal grooveFIREHAWK stentLesion revascularizationCardiac deathComparable safetyStent thrombosisMyocardial infarctionClinical trialsEfficacy profileNoninferiority trialLandmark analysis
2016
Significance of prior percutaneous revascularisation in patients with acute coronary syndromes: insights from the prospective PROSPECT registry.
Iñiguez A, Brener SJ, Jiménez VA, Maehara A, Mintz GS, Xu K, Weisz G, Lansky AJ, De Bruyne B, Serruys PW, Stone GW. Significance of prior percutaneous revascularisation in patients with acute coronary syndromes: insights from the prospective PROSPECT registry. EuroIntervention 2016, 11: 1468-74. PMID: 27107311, DOI: 10.4244/eijv11i13a285.Peer-Reviewed Original ResearchConceptsPrior PCIPrior percutaneous coronary interventionMajor adverse cardiac eventsACS patientsAcute coronary syndrome patientsAdverse cardiac eventsAcute coronary syndromeChronic kidney diseaseCoronary syndrome patientsHigh-risk featuresCongestive heart failureIntravascular ultrasound findingsPercutaneous coronary interventionPrior myocardial infarctionCoronary syndromeCardiac eventsCoronary interventionCardiac deathHeart failurePercutaneous revascularisationKidney diseaseMyocardial infarctionUltrasound findingsIndependent associationMultivariable model
2015
Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials
Brener SJ, Mehran R, Lansky AJ, Ayele GM, Stone GW. Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. European Heart Journal Acute Cardiovascular Care 2015, 5: 449-454. PMID: 26722003, DOI: 10.1177/2048872615624848.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeHORIZONS-AMI trialCoronary syndromeAspirin pretreatmentMyocardial infarctionCardiac deathStent thrombosisSegment elevation acute coronary syndromesST-segment elevation myocardial infarctionElevation acute coronary syndromeAcute coronary syndrome patientsLarge randomized clinical trialsAdverse ischemic eventsTarget vessel revascularizationCoronary syndrome patientsIndependent risk factorElevation myocardial infarctionLarge prospective studiesHigh-risk cohortIncidence of deathRandomized clinical trialsMultivariable regression analysisPrior revascularizationVessel revascularizationIschemic events
2013
Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] Trial)
Caixeta A, Généreux P, Palmerini T, Lansky AJ, Mehran R, Dangas GD, Xu K, Brener SJ, Stone GW. Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] Trial). The American Journal Of Cardiology 2013, 113: 203-210. PMID: 24176063, DOI: 10.1016/j.amjcard.2013.08.035.Peer-Reviewed Original ResearchConceptsMultivessel coronary artery diseaseMajor adverse cardiac eventsSingle-vessel diseasePercutaneous coronary interventionSurgery scoreCoronary interventionClinical outcomesMyocardial infarctionRate of MACETaxus drug-eluting stentsCardiac Surgery (SYNTAX) scoreOverall study cohortAdverse cardiac eventsCoronary artery diseaseDrug-eluting stentsACUITY trialMultivessel diseaseSS tertilesAngiographic predictorsSYNTAX scoreCardiac eventsThird tertileArtery diseaseCardiac deathIndependent predictorsMeta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)
Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW. Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovascular Interventions 2013, 6: 914-922. PMID: 24050859, DOI: 10.1016/j.jcin.2013.05.005.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular AgentsCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMulticenter Studies as TopicMultivariate AnalysisMyocardial InfarctionPaclitaxelPercutaneous Coronary InterventionProportional Hazards ModelsProsthesis DesignRandomized Controlled Trials as TopicRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsPaclitaxel-eluting stentsIschemia-driven target lesion revascularizationMajor adverse cardiac eventsAdverse cardiac eventsTarget lesion revascularizationLesion failureMyocardial infarctionLesion revascularizationCause mortalityCardiac eventsStent thrombosisStent typeEvent ratesTarget lesion failureClinical trial programException of diabetesIndividual patient dataIndividual clinical outcomesCardiac deathComposite endpointClinical outcomesSPIRIT IIClinical trialsCoronary implantationTrial programA randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL, Xu B, Lansky AJ, Yang YJ, Ma CS, Han YL, Chen SL, Li H, Zhang RY, Fu GS, Yuan ZY, Jiang H, Huo Y, Li W, Zhang YJ, Leon MB. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. EuroIntervention 2013, 9: 75-83. PMID: 23685298, DOI: 10.4244/eijv9i1a12.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedAnalysis of VarianceAntineoplastic AgentsChi-Square DistributionChinaCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary StenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleHumansLeast-Squares AnalysisMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPolymersPredictive Value of TestsProspective StudiesProsthesis DesignSirolimusTime FactorsTreatment OutcomeConceptsIschaemia-driven target lesion revascularisationStent late lumen lossTarget vessel myocardial infarctionLate lumen lossTarget lesion failureSingle de novo coronary lesionsDe novo coronary lesionsNovo coronary lesionsCoronary lesionsPrimary endpointCardiac deathI trialNovel abluminal groove-filled biodegradable polymer sirolimus-eluting stentSingle de novo native coronary lesionsDe novo native coronary lesionsBiodegradable polymer sirolimus-eluting stentsNine monthsNative coronary lesionsProbable stent thrombosisTarget lesion revascularisationVessel myocardial infarctionSirolimus-eluting stentsNon-inferiority trialLesion revascularisationEES group
2012
Coronary Plaque Composition, Morphology, and Outcomes in Patients With and Without Chronic Kidney Disease Presenting With Acute Coronary Syndromes
Baber U, Stone GW, Weisz G, Moreno P, Dangas G, Maehara A, Mintz GS, Cristea E, Fahy M, Xu K, Lansky AJ, Wennerblom B, Mathey DG, Templin B, Zhang Z, Serruys PW, Mehran R. Coronary Plaque Composition, Morphology, and Outcomes in Patients With and Without Chronic Kidney Disease Presenting With Acute Coronary Syndromes. JACC Cardiovascular Imaging 2012, 5: s53-s61. PMID: 22421231, DOI: 10.1016/j.jcmg.2011.12.008.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAngina, UnstableAngioplasty, Balloon, CoronaryChronic DiseaseCoronary AngiographyCoronary Artery DiseaseEuropeFemaleFibrosisHeart ArrestHumansKaplan-Meier EstimateKidney DiseasesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionNecrosisPlaque, AtheroscleroticPredictive Value of TestsProspective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeUltrasonography, InterventionalUnited StatesVascular CalcificationConceptsAcute coronary syndromeChronic kidney diseasePercutaneous coronary interventionCoronary plaque compositionNonculprit lesionsPlaque compositionCoronary syndromeAdverse eventsCoronary interventionCardiac deathKidney diseaseMyocardial infarctionNecrotic coreFibrous tissueGreater necrotic coreUntreated nonculprit lesionsRadiofrequency intravascular ultrasoundCoronary atherosclerotic plaque compositionMinimal luminal areaPercentage of plaqueLesion-level analysisIntravascular ultrasound parametersAtherosclerotic plaque compositionCKD patientsCulprit lesion
2011
Prognostic Value of the SYNTAX Score in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) Trial
Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R, Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Prognostic Value of the SYNTAX Score in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) Trial. Journal Of The American College Of Cardiology 2011, 57: 2389-2397. PMID: 21658558, DOI: 10.1016/j.jacc.2011.02.032.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAngioplasty, Balloon, CoronaryCardiac CatheterizationCoronary AngiographyCoronary Artery BypassElectrocardiographyEmergency TreatmentFemaleHeparin, Low-Molecular-WeightHirudinsHospital MortalityHumansItalyKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisPeptide FragmentsPrognosisProportional Hazards ModelsProspective StudiesRecombinant ProteinsRisk AssessmentROC CurveSeverity of Illness IndexStatistics, NonparametricSurvival AnalysisTreatment OutcomeTriageConceptsSegment elevation acute coronary syndromesElevation acute coronary syndromePercutaneous coronary interventionAcute coronary syndromeSYNTAX scoreCoronary syndromeCardiac deathACUITY trialIndependent predictorsPredictive valueTarget vessel revascularization rateStable ischemic heart diseaseTriple-vessel coronary diseaseVessel revascularization rateCardiac mortality rateMyocardial infarction ratePre-specified subgroupsRisk-stratify patientsIschemic heart diseaseAngiographic substudySS tertilesInfarction rateRevascularization ratesCoronary interventionCoronary diseaseLong-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)
Applegate RJ, Yaqub M, Hermiller JB, Sood P, Yu S, Doostzadeh J, Williams JE, Farhat N, Caputo R, Lansky AJ, Cutlip DE, Sudhir K, Stone GW. Long-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial). The American Journal Of Cardiology 2011, 107: 833-840. PMID: 21247538, DOI: 10.1016/j.amjcard.2010.10.069.Peer-Reviewed Original ResearchMeSH KeywordsCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsLogistic ModelsMaleMiddle AgedPaclitaxelProspective StudiesSingle-Blind MethodSirolimusSurvival RateTreatment OutcomeTubulin ModulatorsUnited StatesConceptsPaclitaxel-eluting stentsMajor adverse cardiovascular eventsSPIRIT III trialAdverse cardiovascular eventsCardiovascular eventsIII trialsPrimary clinical end pointLimited long-term dataTarget lesion revascularizationTarget vessel failureEvent-free survivalClinical end pointsEverolimus-Eluting StentsLong-term safetyLesion revascularizationCardiac deathCoronary arteryMyocardial infarctionSPIRIT IIClinical trialsEfficacy profileUnited States sitesLandmark analysisTerm safetyXIENCE V
2010
Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease
Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease. New England Journal Of Medicine 2010, 362: 1663-1674. PMID: 20445180, DOI: 10.1056/nejmoa0910496.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsTarget lesion failureEverolimus-eluting stentsMajor secondary end pointPrimary end pointSecondary end pointsEnd pointMyocardial infarctionIschemia-driven target lesion revascularizationRoutine follow-up angiographyTarget vessel myocardial infarctionComposite rateTarget lesion revascularizationClinical end pointsCoronary artery diseaseSubgroup of patientsFollow-up angiographyEverolimus-ElutingAngiographic findingsPrespecified subgroupsArtery diseaseCardiac deathStent thrombosisPatientsStentsEvaluation of the effects of everolimus‐eluting and paclitaxel‐eluting stents on target lesions with jailed side branches: 2‐year results from the SPIRIT III randomized trial
Applegate R, Hermiller J, Williams J, Gordon P, Doostzadeh J, Cao S, Su X, Sudhir K, Lansky A, Simonton C, Stone G. Evaluation of the effects of everolimus‐eluting and paclitaxel‐eluting stents on target lesions with jailed side branches: 2‐year results from the SPIRIT III randomized trial. Catheterization And Cardiovascular Interventions 2010, 76: 644-651. PMID: 20506356, DOI: 10.1002/ccd.22606.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBiomarkersCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCreatine Kinase, MB FormDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionMyocardiumNecrosisPaclitaxelProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsSeverity of Illness IndexSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeUnited StatesConceptsPaclitaxel-eluting stentsMajor adverse cardiac eventsTwo-year clinical outcomesTAXUS paclitaxel-eluting stentSPIRIT III trialXience V EESAdverse cardiac eventsMyocardial infarction rateUpper normal levelCreatine kinase-MBSide branchesLower ratesThinner stent strutsPeriprocedural increasePeriprocedural myonecrosisPES patientsEES groupIII trialsInfarction rateCardiac eventsSide branch compromiseCardiac deathPES groupClinical outcomesAdverse outcomes
2008
Treatment of diffuse IN-stent restenosis with Drug-Eluting stents vs. intracoronary bEta-raDiation therapy: INDEED Study
Park SW, Lee SW, Bon Kwon Koo, Park DW, Lee SW, Kim YH, Lee CW, Hong MK, Kim JJ, Mori K, Lansky AJ, Mintz GS, Lee MM, Park SJ. Treatment of diffuse IN-stent restenosis with Drug-Eluting stents vs. intracoronary bEta-raDiation therapy: INDEED Study. International Journal Of Cardiology 2008, 131: 70-77. PMID: 18190986, DOI: 10.1016/j.ijcard.2007.09.003.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsIntracoronary brachytherapySES implantationMyocardial infarctionGroup IILate lossGroup IDiffuse ISRAngiographic restenosisSirolimus-eluting stent implantationEnd pointMore effective treatment modalitiesBare-metal ISRAdverse cardiac eventsPrimary end pointSecondary end pointsEffective treatment modalityIn-Stent RestenosisDrug-eluting stentsLesion revascularizationBaseline characteristicsCardiac eventsCardiac deathLower restenosisStent implantation